89. International Collaboration of Epidemiological Studies of Cervical Cancer. “Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies.” The Lancet 370, no. 9599 (2007): 1609–1621; Smith, Jennifer S., Jane Green, Amy Berrington De Gonzalez, Paul Appleby, Julian Peto, Martyn Plummer, Silvia Franceschi, and Valerie Beral. “Cervical cancer and use of hormonal contraceptives: a systematic review.” The Lancet 361, no. 9364 (2003): 1159–1167; Madeleine, Margaret M., Janet R. Daling, Stephen M. Schwartz, Katherine Shera, Barbara McKnight, Joseph J. Carter, Gregory C. Wipf. “Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix.” Cancer Epidemiology and Prevention Biomarkers 10, no. 3 (2001): 171–177.
90. Hendrickson-Jack, Lisa. “FFP 095 | Cervical Cancer & The Pill | Menstrual Suppression | Cervical Dysplasia | Abnormal Pap | No More Periods? The Blessings of the Curse | Dr. Susan Rako.” Fertility Friday Podcast. Podcast Audio, September 9, 2016. fertilityfriday.com/95.
91. Braaten, Kari P., and Marc R. Laufer. “Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine.” Reviews in Obstetrics and Gynecology 1, no. 1 (2008): 2–10; Centers for Disease Control and Prevention. Genital HPV Infection Fact Sheet. (2004). Rockville, MD: CDC National Prevention Information Network.
92. Marks, Morgan, Patti E. Gravitt, Swati B. Gupta, Kai-Li Liaw, Amha Tadesse, Esther Kim, Chailert Phongnarisorn et al. “Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand.” Journal of Infectious Diseases (2011): 1509.
93. Beral, Valerie, Carol Hermon, Clifford Kay, Philip Hannaford, Sarah Darby, and Gillian Reeves. “Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study.” The BMJ 318, no. 7176 (1999): 96–100.
94. Piyathilake, Chandrika J., Olga L. Henao, Maurizio Macaluso, Phillip E. Cornwell, Sreelatha Meleth, Douglas C. Heimburger, and Edward E. Partridge. “Folate is associated with the natural history of high-risk human papillomaviruses.” Cancer Research 64, no. 23 (2004): 8788–8793; Piyathilake, Chandrika J., Maurizio Macaluso, Ilene Brill, Douglas C. Heimburger, and Edward E. Partridge. “Lower red blood cell folate enhances the HPV-16–associated risk of cervical intraepithelial neoplasia.” Nutrition 23, no. 3 (2007): 203–210; Zhao, W., M. Hao, Y. Wang, N. Feng, Z. Wang, W. Wang, J. Wang, and L. Ding. “Association between folate status and cervical intraepithelial neoplasia.” European Journal of Clinical Nutrition (2016); Jia, W.L., L. Ding, Z.Y. Ren, T.T. Wu, W.M. Zhao, S.L. Fan, and J.T. Wang. “Effects of both folic acid, p16 protein expression and their interaction on progression of cervical cancerization.” Chinese Journal of Epidemiology 37, no. 12 (2016): 1647–1652; Hao, Min, Weihong Zhao, Lili Zhang, Honghong Wang, and Xin Yang. “Low folate levels are associated with methylation-mediated transcriptional repression of miR-203 and miR-375 during cervical carcinogenesis.” Oncology Letters 11, no. 6 (2016): 3863–3869; Li, Q.L., L. Ding, J. Nan, C.L. Liu, Z.K. Yang, F. Chen, Y.L. Liang, and J.T. Wang. “Relationship and interaction between folate and expression of methyl-CpG-binding protein 2 in cervical cancerization.” Chinese Journal of Epidemiology 37, no. 7 (2016): 985–991; Bai, Li-Xia, Jin-Tao Wang, Ling Ding, Shi-Wen Jiang, Hui-Jie Kang, Chen-Fei Gao, Xiao Chen, Chen Chen, and Qin Zhou. “Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization.” Asian Pacific Journal of Cancer Prevention 15, no. 21 (2014): 9313–9317.